Crossmark

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

Crossref DOI link: https://doi.org/10.1186/s40425-019-0703-0

Published Online: 2019-08-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yiyin

Xu, Jin

Hua, Jie

Liu, Jiang

Liang, Chen

Meng, Qingcai

Wei, Miaoyan

Zhang, Bo

Yu, Xianjun https://orcid.org/0000-0002-6697-7143
Shi, Si
Funding

Funding for this research was provided by:

National Science Foundation for Distinguished Young Scholars of China (81625016)

National Natural Science Foundation of China (81772555)

National Natural Science Foundation of China (81802352)

Shanghai Sailing Program (17YF1402500)
License Information

Text and Data Mining valid from 2019-08-29
More Information

Article History

Received: 20 January 2019

Accepted: 31 July 2019

First Online: 29 August 2019

Ethics approval and consent to participate

: The study was approved by the FUSCC and the Institutional Research Ethics Committees. Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: The authors declare that they have no competing interests.